^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

TGFBR2 (Transforming Growth Factor Beta Receptor 2)

i
Other names: TGFBR2, Transforming Growth Factor Beta Receptor 2, Transforming Growth Factor, Beta Receptor II (70/80kDa), Transforming Growth Factor Beta Receptor II, TGF-Beta Type II Receptor, TGF-Beta Receptor Type-2, TbetaR-II, TBR-Ii, TGFR-2, TBRII, Transforming Growth Factor, Beta Receptor II Epsilon, Transforming Growth Factor, Beta Receptor II Alpha, Transforming Growth Factor, Beta Receptor II Delta, Transforming Growth Factor, Beta Receptor II Gamma, Transforming Growth Factor Beta Receptor Type IIC, Transforming Growth Factor, Beta Receptor II Beta, Transforming Growth Factor-Beta Receptor Type II, TGF-Beta Receptor Type IIB, TGF-Beta Receptor Type II, TGFbeta-RII, LDS2, MFS2
10d
Alisol B as a novel inhibitor of TβRs suppresses the growth and metastasis of non-small cell lung cancer by inhibiting TGF-β-induced epithelial-mesenchymal transition. (PubMed, Phytomedicine)
Our findings demonstrate that ALB functions as a novel inhibitor of TβRs, effectively suppressing tumor growth and lung metastasis by inhibiting the EMT process both in vitro and in vivo.
Journal
|
TGFBR2 (Transforming Growth Factor Beta Receptor 2) • TGFB1 (Transforming Growth Factor Beta 1)
14d
Deuterium Concentration as a Dual Regulator: Depletion and Enrichment Elicit Divergent Transcriptional Responses in A549 Lung Adenocarcinoma Cells. (PubMed, Int J Mol Sci)
Together, these results indicate that deuterium concentration acts as a bidirectional modulator of gene expression programs in the A549 model, with enrichment broadly elevating oncogenic expression and moderate depletion associated with selective downregulation of genes linked to resistance, signaling, and invasive behavior. Significance: Deuterium depletion is associated with reduced expression of genes involved in multidrug resistance, growth-factor signaling, and transcriptional amplification, revealing deuterium-responsive transcriptional vulnerabilities within the A549 lung adenocarcinoma model.
Journal
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • IL6 (Interleukin 6) • FGFR4 (Fibroblast growth factor receptor 4) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • BIRC5 (Baculoviral IAP repeat containing 5) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • TGFB1 (Transforming Growth Factor Beta 1) • MMP9 (Matrix metallopeptidase 9) • S100A4 (S100 calcium binding protein A4)
17d
Local gene editing of fibroblasts in tumors reveals a new cancer-associated fibroblast state. (PubMed, J Exp Med)
Combinatorial gene KOs in CAFs reveals a circuit where these Col18a1hi CAFs reshape the TME by recruiting Siglec-Fhi neutrophils via Cxcl5 expression, and where this Col18a1hi CAF cell state is dependent on TNFR1 and canonical Wnt signaling. Together, a fast, affordable, and modular engineering method is demonstrated, allowing discovery of modified fibroblast identities and local intercellular relationships in the TME.
Journal
|
TGFBR2 (Transforming Growth Factor Beta Receptor 2) • TNFRSF1A (TNF Receptor Superfamily Member 1A) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • IL1R1 (Interleukin 1 receptor, type I) • OSMR (Oncostatin M Receptor)
17d
Sphingosine-1-phosphate promotes CD8 T cell exhaustion in breast cancer via exosomal transfer of TGFBR2. (PubMed, Cell Death Dis)
In vivo administration of exosomes derived from S1P-treated murine breast cancer cells in a breast cancer allograft model markedly promoted tumor growth and heightened CD8 T cell exhaustion, whereas exosomes from TGFBR2-silenced, S1P-treated cells exerted the reverse effect, underscoring the pivotal role of the S1P-TGFBR2 axis in modulating the tumor microenvironment. These findings suggest that targeting the S1P-TGFBR2 pathway could enhance antitumor immunity in breast cancer.
Journal
|
CD8 (cluster of differentiation 8) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • CREB1 (CAMP Responsive Element Binding Protein 1) • RAB27A (RAB27A, Member RAS Oncogene Family)
24d
Single-cell epigenetic landscape, microenvironment interactions, and gene regulatory modules of non-functioning pituitary adenomas. (PubMed, Cell Syst)
Our study provides insight into the altered epigenetic gene control landscape and TME processes of the NFPA tumor phenotype. Our data are freely available at https://rstudio-connect.hpc.mssm.edu/nfpa_browser/.
Journal
|
CCND1 (Cyclin D1) • CDK6 (Cyclin-dependent kinase 6) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • MEF2C (Myocyte Enhancer Factor 2C) • SFRP1 (Secreted frizzled related protein 1) • FZD6 (Frizzled Class Receptor 6) • PBX3 (PBX Homeobox 3)
1m
Dental pulp stem cells maintain epigenetic chromatin architecture remodeling primed by the etiological stimulus of biliary atresia. (PubMed, Stem Cell Res Ther)
The present epigenetic memory in BA-SHED implies that BA-SHED imprint bile duct deficiency through TGFBR2 dysregulated by the HNF6 promoter activation epigenetically. Thus, BA-SHED are a potential model for expanding our knowledge in BA research.
Journal
|
IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • TGFBR2 (Transforming Growth Factor Beta Receptor 2)
1m
Matrix stiffness-induced YEATS2 drives HCC progression via epigenetic activation of the TGFBR2-TAZ-AKT pathway. (PubMed, Cell Death Differ)
Moreover, increased matrix stiffness was found to induce YEATS2 expression through augmenting the binding of HIF-1α to the YEATS2 promoter. Collectively, these results delineate a novel YEATS2-TGFBR2-TAZ-AKT signaling axis that connects matrix stiffness to metabolic reprogramming and HCC progression, highlighting YEATS2 as a potential therapeutic target for HCC.
Journal
|
HIF1A (Hypoxia inducible factor 1, alpha subunit) • TGFBR2 (Transforming Growth Factor Beta Receptor 2)
2ms
Single-cell and spatial transcriptome analyses reveal tumor immunometabolism in lymph node metastasis of lung cancer. (PubMed, Cancer Biol Med)
This study delineated transcriptional differences between primary tumors and MetLNs in lung cancer, thereby providing a foundation for further exploration of LN metastasis.
Journal
|
GDF15 (Growth differentiation factor 15) • TGFBR2 (Transforming Growth Factor Beta Receptor 2)
2ms
New P1/2 trial
|
MSI (Microsatellite instability) • TGFBR2 (Transforming Growth Factor Beta Receptor 2)
|
MSI-H/dMMR
|
Erbitux (cetuximab) • cyclophosphamide • fludarabine IV
2ms
Ligand-dependent Wnt signaling promotes gastric cancer metastasis through hyaluronan expression in microenvironment. (PubMed, Nat Commun)
Strikingly, hyaluronidase expression in WKTP cells significantly suppresses liver metastasis. Here we show the critical role of ligand-dependent Wnt signaling and Has2-mediated hyaluronan deposition in metastasis, offering potential therapeutic strategy against gastric cancer metastasis.
Journal
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • HAS2 (Hyaluronan Synthase 2)
2ms
Hypoxia-Induced TGFBI Promotes Bladder Cancer Progression by Creating a Stemness Regulation Loop through Stabilizing the Disulfide Bonds of GDF15. (PubMed, Research (Wash D C))
TGFBI knockdown or GDF15 inhibition results in a decrease in functional proteins associated with stemness maintenance, which suppresses bladder CSCs' self-renewal and effectively improves the efficacy of chemotherapy. Together, these findings demonstrate the pivotal role of TGFBI in BLCA's stemness maintenance and BLCA progression, highlighting that the inhibition of the TGFBI/GDF15 axis is a potential therapeutic strategy for the amelioration of cancer chemotherapy.
Journal
|
GDF15 (Growth differentiation factor 15) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • TGFB1 (Transforming Growth Factor Beta 1) • TGFBI (Transforming Growth Factor Beta Induced)
2ms
Convergence for Inactivation of TGF-β Signaling Is a Common Feature of Advanced Pancreatic Cancer. (PubMed, Cancer Discov)
No functionally deleterious driver gene mutations were identified that were attributed to treatment, although radiated PDACs had significantly greater genomic complexity and distinct mutational signatures compared to PDACs managed by chemotherapy. These findings provide a high-level profile of the genetic features distinguishing locally advanced from metastatic PDAC, potentially serving as a biomarker of borderline resectable or locally advanced PDACs most likely to benefit from neoadjuvant chemoradiation.
Journal
|
SMAD4 (SMAD family member 4) • TGFBR2 (Transforming Growth Factor Beta Receptor 2) • TGFB1 (Transforming Growth Factor Beta 1)